Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-28
DOI
10.1038/s41598-020-69228-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the diagnosis and treatment of latent tuberculosis infection
- (2020) Ye Eun (Grace) Jung et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy
- (2020) Lauren R Cirrincione et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
- (2019) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice
- (2019) Shetty Ravi Dyavar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Protein Binding of First-Line Antituberculosis Drugs
- (2018) Wael A. Alghamdi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
- (2018) Simon Tiberi et al. LANCET INFECTIOUS DISEASES
- Mycobacterium tuberculosis
- (2018) Anastasia Koch et al. TRENDS IN MICROBIOLOGY
- Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay
- (2018) Shetty Ravi Dyavar et al. Scientific Reports
- Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions
- (2017) Pankajini Mallick et al. Expert Opinion on Drug Metabolism & Toxicology
- Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?
- (2017) Chunlan Zheng et al. Drug Design Development and Therapy
- Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
- (2015) K L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
- (2015) Anthony T. Podany et al. CLINICAL INFECTIOUS DISEASES
- Detecting latent tuberculosis in compromised patients
- (2015) Ilaria Sauzullo et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus
- (2015) Katharina Ronacher et al. IMMUNOLOGICAL REVIEWS
- Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist
- (2015) Brian W. Ogilvie et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC/MS/MS
- (2015) Lee C. Winchester et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Parsing interindividual drug variability: an emerging role for systems pharmacology
- (2015) Richard M. Turner et al. Wiley Interdisciplinary Reviews-Systems Biology and Medicine
- Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins
- (2014) Mario Regazzi et al. CLINICAL PHARMACOKINETICS
- Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine
- (2013) Beth Williamson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Causal analysis approaches in Ingenuity Pathway Analysis
- (2013) Andreas Krämer et al. BIOINFORMATICS
- Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers
- (2013) M. Weiner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques
- (2012) Ravi Dyavar Shetty et al. JOURNAL OF CLINICAL INVESTIGATION
- World Health Organization Group 5 Drugs for the Treatment of Drug-Resistant Tuberculosis: Unclear Efficacy or Untapped Potential?
- (2012) K. E. Dooley et al. JOURNAL OF INFECTIOUS DISEASES
- Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa
- (2012) Lukas Fenner et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4, and HepaRG Cells
- (2011) I. E. Templeton et al. DRUG METABOLISM AND DISPOSITION
- Tuberculosis and cancer: a complex and dangerous liaison
- (2011) Sandro Vento et al. LANCET ONCOLOGY
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
- (2011) Timothy R. Sterling et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Pregnane X Receptor (NR1I2) and CYP2B6 Genetic Polymorphisms on the Induction of Bupropion Hydroxylation by Rifampin
- (2010) J. Y. Chung et al. DRUG METABOLISM AND DISPOSITION
- Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation
- (2010) Diana M. Brainard et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression
- (2010) A. Git et al. RNA
- Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
- (2009) L. A. Wenning et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Polymorphism of human cytochrome P450 enzymes and its clinical impact
- (2009) Shu-Feng Zhou et al. DRUG METABOLISM REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More